Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Accuracy and Clinical Impact of 68-Ga-labeled Octreotide Analogues PET in Diagnosis and Staging of Duodenal-pancreatic Neuroendocrine Tumours; Proposal of a Multicenter, Prospective Clinical Trial

NCT01673906 is registered in ClinicalTrials.gov with Azienda USL Reggio Emilia - IRCCS as lead sponsor.

NCT NCT01673906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01673906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Accuracy and Clinical Impact of 68-Ga-labeled Octreotide Analogues PET in Diagnosis and Staging of Duodenal-pancreatic Neuroendocrine Tumours; Proposal of a Multicenter, Prospective Clinical Trial
Lead sponsor
Azienda USL Reggio Emilia - IRCCS
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2012
Completion date
July 5, 2016
Enrollment
142 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumours